Table1.
Acute myeloid leukemia and related myeloid neoplasms
| Acute myeloid leukemia with recurrent genetic abnormalities |
| AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 |
| AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 |
| APL with t(15;17)(q22;q12); PML-RARA |
| AML with t(9;11)(p22;q23); MLLT3-MLL |
| AML with t(6;9)(p23;q34); DEK-NUP214 |
| AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 |
| AML (megakaryoblastic) with t(91;22)(p13;q13); RBM15-MKL1 |
| Provisional entity: AML with mutated NPM1 |
| Provisional entity: AML with mutated CEBPA |
| Acute myeloid leukemia with myelodysplasia-related changes |
| Therapy-related myeloid neoplasms |
| Acute myeloid leukemia, not otherwise specified |
| AML with minimal differentiation |
| AML without maturation |
| AML with maturation |
| Acute myelomonocytic leukemia |
| Acute monoblastic/monocytic leukemia |
| Acute erythroid leukemia |
| Pure erythroid leukemia |
| Erythroleukemia, erythroid/myeloid |
| Acute megakaryoblastic leukemia |
| Acute basophilic leukemia |
| Acute panmyelosis with myelofibrosis |
| Myeloid sarcoma |
| Myeloid proliferations related to Down syndrome |
| Transient abnormal myelopoiesis |
| Myeloid leukemia associated with Down syndrome |
| Blastic plasmacytoid dendritic cell neoplasms |